Biotech Archives - Page 21 of 795

1 minute read

Johnson & Johnson Pivotal Study Of Seltorexant Shows Clinically Meaningful Improvement In Depressive Symptoms And Sleep Disturbance Outcomes

May 29, 12:18 PM

https://www.jnj.com/media-center/press-releases/johnson-johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes&nbs

JNJ

1 minute read

Mira Pharmaceuticals Announces That The DEA Has Ruled ‘MIRA-55 Not Classified As A Controlled Substance’

By Benzinga Newsdesk

May 29, 8:54 AM

Ruling removes potential complications for manufacturing, pre-clinical development, IND submission, clinical development, and ultimately commercialization.MIAMI, May 29, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.

MIRA

2 minute read

CareDx Responds To Natera’s Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The ‘544 Patent.

By Benzinga Newsdesk

May 29, 8:31 AM

CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ:CDNA) – The

CDNA

1 minute read

Amid Ozempic’s ‘Miracle’ Weight-Loss Craze, This Company Peaked Over 100% In Tuesday Pre-Market After Receiving Approval For Obesity Treatment

By Pooja Rajkumari

May 29, 7:49 AM

The approval comes at a time when global demand for weight loss drugs like Ozempic and WeGovy is increasing.

RSLS

2 minute read

Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence

By Benzinga Neuro

May 29, 4:36 AM

Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing eye-care market.

MRK

1 minute read

NANOBIOTIX To Present Of new Data From Phase 1 Immunotherapy Program At The 2024 ASCO Annual Meeting Followed By An Investor Conference Call

By Benzinga Newsdesk

May 28, 4:21 PM

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer

NBTX

2 minute read

Arcturus Therapeutics’ Early Cystic Fibrosis Trial Results Encouraging – Analyst Cautiously Optimistic

By Vandana Singh

May 28, 2:55 PM

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.

ARCT

2 minute read

With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward

By Vandana Singh

May 28, 2:40 PM

RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.

PFE

2 minute read

Why Is AstraZeneca Stock Trading Lower On Tuesday?

By Vandana Singh

May 28, 2:32 PM

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

AZN

1 minute read

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?

By Vandana Singh

May 28, 1:00 PM

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

AGIO